MedicalSystem has obtained a medical device registration certificate from the Zhejiang Medical Products Administration for its Alpha-1 Antitrypsin Test Kit, which uses an immunoturbidimetric method. The certificate is valid from July 17, 2026, to July 16, 2031. The product is intended for the in vitro quantitative determination of alpha-1 antitrypsin in human serum. In the first quarter of 2026, MedicalSystem achieved revenue of 376 million yuan and a net profit attributable to the parent company of 33.77 million yuan.
Ningbo MedicalSystem Biotechnology Co LtdObtained medical device registration certificate for Alpha-1 Antitrypsin Test Kit, enabling market access.